𝔖 Bobbio Scriptorium

✦ LIBER ✦

Efficacy and Safety of Unfractionated Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Revascularization for an Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials Performed With Stents and Thienopyridines

✍ Scribed by David E. Winchester; William D. Brearley; Xuerong Wen; Ki E. Park; Anthony A. Bavry

Book ID: 112061414
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 574 KB
Volume: 35
Category: Article
ISSN: 0160-9289
DOI: 10.1002/clc.20974

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Comparison of Intracoronary with Intra

A Comparison of Intracoronary with Intravenous Glycoprotein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials

✍ GANG FU; LEI JIA; XIN ZHAO; YIBO WANG; XIAOHUI CHEN; YANG YANG; NA LU; WEI ZHAO; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 793 KB

Randomized evaluation of the safety and

Randomized evaluation of the safety and efficacy of enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide

✍ S.G. Goodman; D. Fitchett; P.W. Armstrong; M. Tan; A. Langer 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Efficacy and safety of enoxaparin compar

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial

✍ Harvey D. White; Neal S. Kleiman; Kenneth W. Mahaffey; Yuliya Lokhnygina; Karen 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 333 KB

Randomized evaluation of the efficacy of

Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial

✍ David H. Fitchett; Anatoly Langer; Paul W. Armstrong; Mary Tan; Aurora Mendelsoh 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 142 KB

The Efficacy and Safety of Prasugrel Wit

The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention: A TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis In Myocardial Infarction 38) Analysis

✍ Michelle O'Donoghue; Elliott M. Antman; Eugene Braunwald; Sabina A. Murphy; P. G 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 480 KB